Since 1984, the number of biotechnology companies listed on the Taiwan Stock Exchange has gone from precisely zero to more than 100, with a combined value of US$25 billion. The government in Taipei can take some of the credit for this after identifying the industry as the next Big Thing to promote after its success […]
https://www.prnewswire.com/news-releases/pharmaessentia-and-aop-orphan-receive-positive-chmp-opinion-for-besremi-ropeginterferon-alfa-2b-for-treatment-of-polycythemia-vera-pv-in-eu-300767190.html WALTHAM, Mass., Dec. 17, 2018 /PRNewswire/ — PharmaEssentia, a global biopharmaceutical company focused on developing and commercializing novel treatments for treatment of rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Besremi, intended for the […]
Press Release from AOP Orphan Pharmaceuticals AG Vienna, Austria December 4, 2018 High rates of durable hematological response and symptom control with good tolerability were reconfirmed with Ropeginterferon alfa-2b after 36 months of treatment. Disease Modification by Ropeginterferon alfa-2b was illustrated by high molecular response rates, associated with the ability to reduce allelic burden […]
36 month analysis of ropeginterferon alfa-2b (Ropeg) phase III clinical data in Polycythemia Vera (PV) demonstrates superiority across three key aspects of disease control, including complete hematological response (CHR), disease burden, and molecular response A long-term development partner of Ropeg, AOP Orphan’s submission for marketing authorization of ropeginterferon alfa-2b in the EU is in the […]
Myeloproliferative Syndromes: Clinical Program: Oral and Poster Abstracts Type: Oral Session: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials with Agents Other Than JAK Inhibitors Sunday, December 4, 2016: 4:30 PM Marriott Grand 8-9 (Marriott Marquis San Diego Marina) Heinz Gisslinger, MD1, Christoph Klade2*, Pencho Georgiev3*, AleksanderSkotnicki, MD, PhD4, Liana Gercheva-Kyuchukova, MD5*, Miklos Egyed6, Viktor Rossiev, MD7*, […]
Meredith ManningMeredith Manning joined PharmaEssentia as General Manager for the U.S. in 2020, bringing with her more than 20 years of experience in global commercialization and brand building for biopharmaceuticals and medical devices. She was most recently Chief Commercial Officer at resTORbio™, and previously served as Vice President of Global Product Strategy in Hemophilia for Shire (formerly Baxalta) and Baxter. She previously held a series of marketing leadership roles at Vertex® and Pfizer.
Meredith received a B.S. at Colorado College and an MBA from the University of Chicago Booth School of Business.
Jack Hwang, Ph.D.Jack Hwang joined PharmaEssentia in 2006 and has served as General Manager in Taiwan since 2015. With training in organic chemistry, he has held a series of leadership roles at prior companies, including as Senior Director at Optimer Pharmaceuticals, Senior Group Leader at Array BioPharma®, and earlier as a research scientist at Amgen® and Ligand® Pharmaceuticals.
Jack completed his Ph.D. in organic chemistry and post-doctoral fellowship in natural product synthesis at the University of Pennsylvania.
Albert Qin, M.D. Ph.D.Albert Qin, who joined PharmaEssentia in 2017, brings more than 20 years of experience in the biotech and pharmaceutical industry with an emphasis on clinical development. Recent leadership roles include Chief Medical Officer at China Health Group, Chief Scientific Officer and Corporate Officer at SymBio Pharmaceuticals, and Medical Director at ImmunoGen™. Earlier in his career, he held clinical development and R&D roles at Pfizer, Bayer and Biogen®. At Biogen, he did innovative research and made discoveries related to cytokines, immunology, and gene therapy.
Albert completed his medical degree in the Department of Medicine at Shandong Medical University in China and his Ph.D. in biochemistry and molecular pharmacology at Harvard Medical School. He completed a visiting research fellowship at Brigham and Women’s Hospital.
Ching-Leou Teng, Ph.D.Ching-Leou Teng offers extensive pharmaceutical science and development expertise to the PharmaEssentia team. After joining the company as head of operations in 2003, she became Chairperson in 2009. Prior to PharmaEssentia, Ching-Leou held multiple leadership roles in drug delivery research and pharmaceutical development at Ionis™ (formerly ISIS) Pharmaceuticals, and previously served as a reviewer in the Pharmacokinetics Evaluation Branch of the Division of Biopharmaceutics at the Food and Drug Administration (FDA). Early in her career, Ching-Leou was a registered pharmacist at hospitals in Taiwan.
Ching-Leou completed her B.S. in pharmacy at Taipei Medical College, followed by an M.S. in pharmaceutical science at North Dakota State University. She completed her Ph.D. and post-doctoral fellowship at the University of Michigan.
Ko-Chung Lin, Ph.D.Ko-Chung Lin has led PharmaEssentia since 2002, driven by rich and diverse career experiences at leading U.S. pharmaceutical companies. He is recognized for medicinal chemistry advances in pegylation, including the invention of pegylated-interferon, that have led to the development and successful entry of multiple leading therapeutics. Prior to PharmaEssentia, Ko-Chung was head of the Adentri® and pegylated-Avonex® programs at Biogen®. Earlier in his career, he contributed to inventions in HIV in his research roles at Monsanto.
Ko-Chung received B.S. and M.S. degrees in chemistry from National Taiwan Normal University, his Ph.D. from the University of Missouri, and completed a post-doctoral fellowship at the University of Michigan.